Asterias Biotherapeutics Inc (AST) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Asterias Biotherapeutics Inc (NYSEMKT:AST) announced its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.07. The firm earned $2.10 million during the quarter, compared to analyst estimates of $1.50 million.
Asterias Biotherapeutics (NYSEMKT:AST) opened at 4.40 on Wednesday. The firm’s 50 day moving average price is $3.74 and its 200 day moving average price is $3.34. The stock’s market cap is $199.84 million. Asterias Biotherapeutics has a one year low of $2.30 and a one year high of $5.75.
Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Asterias Biotherapeutics in a report on Sunday, September 11th. Zacks Investment Research lowered Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 19th. Finally, FBR & Co reissued a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, August 31st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Asterias Biotherapeutics currently has an average rating of “Buy” and an average price target of $7.75.
In other Asterias Biotherapeutics news, COO Katharine E. Spink sold 19,336 shares of the business’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $3.52, for a total value of $68,062.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Edward Wirth sold 14,760 shares of the business’s stock in a transaction on Friday, September 9th. The stock was sold at an average price of $3.52, for a total transaction of $51,955.20. The disclosure for this sale can be found here.
A number of institutional investors have recently modified their holdings of AST. Bank of New York Mellon Corp raised its stake in shares of Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock worth $131,000 after buying an additional 19,469 shares during the period. Highbridge Capital Management LLC bought a new stake in shares of Asterias Biotherapeutics during the third quarter worth about $151,000. BlackRock Investment Management LLC raised its stake in shares of Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock worth $176,000 after buying an additional 36,782 shares during the period. KCG Holdings Inc. raised its stake in shares of Asterias Biotherapeutics by 273.3% in the third quarter. KCG Holdings Inc. now owns 72,989 shares of the company’s stock worth $309,000 after buying an additional 53,438 shares during the period. Finally, Sabby Management LLC bought a new stake in shares of Asterias Biotherapeutics during the second quarter worth about $741,000.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.